Regulatory effect of physcion on induced apoptosis in hepatocellular carcinoma by miR-370

doi:10.3877/cma.j.issn.2095-5782.2018.02.012

Abstract

Abstract:

Objective:

To observe and investigate the mechanism of induced apoptosis of hepatic cell carcinoma by miR-370.

Methods:

HCC cell lines (SMMC7721 and HepG2) were treated with physcion. MiR-370 expression was quantified by real time PCR with a TaqMan Probe and mRNA expression of Sp1 and DNMT1 was quantified by Western blot.

Results:

Physcion suppressed cell growth of HCC cells and increased the apoptotic proportion in both cell lines. Physcion induced apoptosis in HCC cells through upregulating miR-370. Our findings showed that the physcion modulated the level of miR-370 through AMPK/Sp1/DNMT1 signaling (P<0.01) .

Conclusions:

Physcion exerts anti-tumor effect against HCC, and may be a potential agent for the adjunct chemotherapy.

Key words: Physcion, Hepatocellular carcinoma, miR-370, DNMT1, Sp1

Yan Li, Xiaoping Pan, Haixia Wang, Dongmeng Tong, Chen Wang, Lida Zhu. Regulatory effect of physcion on induced apoptosis in hepatocellular carcinoma by miR-370[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2018, 06(02): 148-153.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2018.02.012

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2018/V06/I02/148

Figures/Tables 4

References 35

[1]	Vilarinho S, Taddei T. Therapeutic strategies for hepatocellular carcinoma：new advances and challenges[J]. Curr Treat Options Gastroenterol, 2015, 13(2):219-234.
[2]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[3]	Song P, Feng X, Zhang K, et al. Perspectives on using des-gamma-carboxyprothrombin（DCP）as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China[J]. Hepatobiliary Surg Nutr, 2013, 2(4):227-231.
[4]	Zuo TT, Zheng RS, Zhang SW, et al. Incidence and mortality of liver cancer in China in 2011[J]. Chin J Cancer, 2015, 34(11):508-513.
[5]	Hébrant A, Floor S, Saiselet M, et al. miRNA expression in anaplastic thyroid carcinomas[J]. PLoS One, 2014, 9(8):e103871.
[6]	Ong SG, Lee WH, Kodo K, et al. MicroRNA-mediated regulation of differentiation and trans-differentiation in stem cells[J]. Adv Drug Deliv Rev, 2015, 88 3-15.
[7]	Ziari K, Zarea M, Gity M, et al. Retraction Note to：Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker[J]. Tumour Biol, 2016, Nov 5. [Epub ahead of print]
[8]	Shi YH, Qi BB, Liu XB, et al. Upregulation of miR-522 is associated with poor outcome of hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci, 2016, 20(15):3194-3198.
[9]	Xu WP, Yi M, Li QQ, et al. Perturbation of MicroRNA-370/Lin-28 homolog A/nuclear factor kappa B regulatory circuit contributes to the development of hepatocellular carcinoma[J]. Hepatology, 2013, 58(6):1977-1991.
[10]	Sun G, Hou YB, Jia HY, et al. MiR-370 promotes cell death of liver cancer cells by Akt/FoxO3a signalling pathway[J]. Eur Rev Med Pharmacol Sci, 2016, 20(10):2011-2019.
[11]	Agarwal SK, Singh SS, Verma S, et al. Antifungal activity of anthraquinone derivatives from Rheum emodi[J]. J Ethnopharmacol, 2000, 72(1-2):43-46.
[12]	Tamokou Jde D, Tala MF, Wabo HK, et al. Antimicrobial activities of methanol extract and compounds from stem bark of Vismia rubescens[J]. J Ethnopharmacol, 2009, 124(3):571-575.
[13]	Hong JY, Chung HJ, Bae SY, et al. Induction of cell cycle arrest and apoptosis by physcion, an anthraquinone isolated from rhubarb（rhizomes of rheum tanguticum）, in MDA-MB-231 human breast cancer cells[J]. J Cancer Prev, 2014, 19(4):273-278.
[14]	Chen X, Gao H, Han Y, et al. Physcion induces mitochondria-driven apoptosis in colorectal cancer cells via downregulating EMMPRIN[J]. Eur J Pharmacol, 2015, 764:124-133.
[15]	Han YT, Chen XH, Gao H, et al. Physcion inhibits the metastatic potential of human colorectal cancer SW620 cells in vitro by suppressing the transcription factor SOX2[J]. Acta Pharmacol Sin., 2015, 37(2):264-275.
[16]	Ge HM, Song YC, Shan CY, et al. New and cytotoxic anthraquinones from Pleospora sp. IFB-E006, an endophytic fungus in Imperata cylindrical[J]. Planta Med, 2005, 71(11):1063-1065.
[17]	Lin R, Elf S, Shan C, et al. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling[J]. Nat Cell Biol, 2015, 17(11):1484-1496.
[18]	Yungang W, Xiaoyu L, Pang T, et al. miR-370 targeted FoxM1 functions as a tumor suppressor in laryngeal squamous cell carcinoma（LSCC）[J]. Biomed Pharmacother, 2014, 68(2):149-154.
[19]	Zhang X, Zeng J, Zhou M, et al. The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia[J]. Mol Cancer, 2012, 11:56.
[20]	An F, Yamanaka S, Allen S, et al. Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch[J]. PLoS One, 2012, 7(10):e45606.
[21]	Chen XP, Chen YG, Lan JY, et al. MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG[J]. Cancer Lett, 2014, 353(2):201-210.
[22]	Cao X, Liu D, Yan X, et al. Stat3 inhibits WTX expression through up-regulation of microRNA-370 in Wilms tumor[J]. FEBS Lett, 2013, 587(6):639-644.
[23]	Wu Z, Sun H, Zeng W, et al. Upregulation of MircoRNA-370 Inducesproliferation in humanprostatecancercells by downregulating the transcriptionfactor FOXO1[J]. PLoS One, 2012, 7(9):e45825.
[24]	Fan C, Liu S, Zhao Y, et al. Upregulation of miR-370 contributes to the progression of gastric carcinoma via suppression of FOXO1[J]. Biomedecine & pharmacotherapie, 2013, 67(6):521-526.
[25]	Sim J, Ahn H, Abdul R, et al. High MicroRNA-370 Expression Correlates with Tumor Progression and Poor Prognosis in Breast Cancer[J]. J Breast Cancer, 2015, 18(4):323-328.
[26]	Pan XP, Huang LH, Wang X. MiR-370 functions as prognostic marker in patients with hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci, 2017, 21: 3581-3585.
[27]	Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction[J]. Nat Rev Cancer, 2006, 6(2):107-116.
[28]	Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained[J]. Nat Rev Genet, 2009, 10(11):805-811.
[29]	Brenner C, Fuks F. DNA methyltransferases：facts, clues, mysteries[J]. Curr Top Microbiol Immunol, 2006, 301:45-66.
[30]	Yan L, Yang X, Davidson NE. Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer[J]. J Mammary Gland Biol Neoplasia, 2001, 6(2):183-192.
[31]	Saito Y, Kanai Y, Nakagawa T, et al. Increased protein expression of DNA methyltransferase（DNMT）1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas[J]. Int J Cancer, 2003, 105(4):527-532.
[32]	Zhu YZ, Zhu R, Shi LG, et al. Hepatitis B virus X protein promotes hypermethylation of p16（INK4A）promoter through upregulation of DNA methyltransferases in hepatocarcinogenesis[J]. Exp Mol Pathol, 2010, 89(3):268-275.
[33]	Li J, Zou WX, Chang KS. Inhibition of Sp1 functions by its sequestration into PML nuclear bodies[J]. PLoS One, 2014, 9(4):e94450.
[34]	Sontag RL, Weber TJ. Ectopic ERK expression induces phenotypic conversion of C10 cells and alters DNA methyltransferase expression[J]. BMC Res Notes, 2012, 5:217.
[35]	Zhao S, Wu J, Zheng F, et al. β-elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKα signalling pathways in human lung cancer cells：the role of Sp1[J]. J Cell Mol Med, 2015, 19(3):630-641.

Please choose a citation manager

Content to export